FDA Grants Denali First Commercial Drug Approval on March 25
Denali Therapeutics (Nasdaq: DNLI) secured a landmark U.S. Food and Drug Administration (FDA) accelerated approval on March 25, 2026, for its drug Avlayah (tividenofusp alfa-eknm). The decision marks the company's transition into a commercial-stage entity and provides the first new approved treatment for Hunter syndrome (MPS II) in nearly 20 years. Avlayah is an enzyme replacement therapy indicated for pediatric patients with neurologic manifestations of the disease.
The approval allows Denali to begin marketing its first product, creating a new revenue stream for the company. Hunter syndrome is a rare genetic disease affecting approximately 500 individuals in the United States and 2,000 worldwide, representing a focused market with a significant unmet medical need. Denali announced it would host a conference call on March 25 at 12:30 p.m. UTC-5 to discuss the approval.
Avlayah Shows 91% Biomarker Reduction by Crossing Blood-Brain Barrier
The FDA's decision was underpinned by data from a Phase 1/2 clinical trial showing Avlayah's powerful effect on a key disease biomarker. The therapy achieved a 91% reduction in cerebrospinal fluid (CSF) heparan sulfate from baseline by the 24th week of treatment. This result is particularly significant because it was achieved by successfully crossing the blood-brain barrier, a long-standing challenge in treating neurological disorders.
This success serves as a critical validation for Denali's proprietary TransportVehicle™ (TV) platform, which is engineered to deliver large therapeutic molecules into the brain. The platform's validation could de-risk other drug candidates in Denali's pipeline that target a wide range of neurodegenerative diseases.
This milestone validates our TransportVehicle platform and its potential to overcome the long-standing challenge of delivering biologic medicines across the blood-brain barrier, with the aim to transform the treatment of a wide range of neurodegenerative diseases.
— Ryan Watts, Ph.D., Co-founder and Chief Executive Officer of Denali Therapeutics.
Approval Unlocks New Revenue and Valuable Priority Review Voucher
Beyond establishing its first commercial revenue stream, Denali also gains a significant financial asset. In connection with the approval, the FDA granted the company a Rare Pediatric Disease Priority Review Voucher (PRV). These vouchers can be used to expedite the FDA review of a future drug application from six months down from the standard ten months, or they can be sold to other pharmaceutical companies. PRVs have historically commanded prices ranging from tens of millions to over one hundred million dollars, providing a source of non-dilutive capital.
The continued approval for Avlayah may depend on the verification of clinical benefit in a confirmatory Phase 2/3 trial, which is currently enrolling participants. However, this initial green light establishes a new standard of care and provides a critical proof-of-concept for Denali's broader therapeutic strategy.
